Velan Capital Investment Management LP Adma Biologics, Inc. Transaction History

Velan Capital Investment Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$4.4 - $6.74 $2.67 Million - $4.09 Million	-607,499 Reduced 28.44%	1,528,601 $10.1 Million
Q4 2023 Feb 14, 2024	BUY	$3.08 - $4.52 $1.23 Million - $1.81 Million	400,000 Added 23.04%	2,136,100 $9.66 Million
Q3 2023 Nov 13, 2023	SELL	$3.47 - $4.61 $3.44 Million - $4.56 Million	-989,951 Reduced 36.31%	1,736,100 $6.22 Million
Q2 2023 Aug 11, 2023	SELL	$3.12 - $4.22 $3.97 Million - $5.38 Million	-1,273,949 Reduced 31.85%	2,726,051 $10.1 Million
Q4 2022 Feb 13, 2023	SELL	$2.47 - $3.88 $3.13 Million - $4.92 Million	-1,269,155 Reduced 24.09%	4,000,000 $15.5 Million
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $1.63 Million - $2.3 Million	-804,443 Reduced 13.24%	5,269,155 $12.8 Million
Q2 2022 Aug 15, 2022	BUY	$1.43 - $2.2 $358,644 - $551,760	250,800 Added 4.31%	6,073,598 $12 Million
Q1 2022 May 16, 2022	BUY	$1.28 - $1.83 $544,000 - $777,750	425,000 Added 7.87%	5,822,798 $10.7 Million
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.66 $5.88 Million - $8.96 Million	5,397,798 New	5,397,798 $7.61 Million

318

184M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.76B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Velan Capital Investment Management LP, based on Form 13F filings with the SEC.

Stay updated on Velan Capital Investment Management LP with notifications on news.